Evidence map›Paper›PMID 34652499›Full record

ArticlePsychopharmacology2022

Additive roles of tobacco and cannabis co-use in relation to delay discounting in a sample of heavy drinkers.

Steven J Nieto, Alexandra Venegas, Elizabeth M Burnette, James MacKillop, Lara A Ray

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Steven J NietoDepartment of Psychology, University of California Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Alexandra VenegasDepartment of Psychology, University of California Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Elizabeth M BurnetteDepartment of Psychology, University of California Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
James MacKillopDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
Lara A RayDepartment of Psychology, University of California Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. lararay@psych.ucla.edu.
University of California, Los Angeles · USMcMaster University · CA

Funding

UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use DisorderR01AA026190 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2018 to 2021
$2.7M
Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
Applying behavioral economics to screen medications for alcohol use disorderF32AA029288 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NIETO, STEVEN J · 2021 to 2022
$115k
Probing Inflammation and Reward Sensitivity in Alcohol Use DisorderF31AA028976 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BURNETTE, ELIZABETH · 2020 to 2022
$103k
NIAAA NIH HHS F31 AA028976NIAAA NIH HHS F31AA028976NIAAA NIH HHS F32 AA029288NIAAA NIH HHS F32AA029288NIAAA NIH HHS K24 AA025704NIAAA NIH HHS K24AA025704NIAAA NIH HHS R01 AA026190NIAAA NIH HHS R01AA026190-02S1NIDA NIH HHS T32 DA024635NIDA NIH HHS T32DA024635
6 · The paper itself

Abstract

rationaleAlcohol use disorder (AUD) is associated with steeper delay discounting rates; however, it is unknown whether substance co-use, particularly cannabis use, has an additive effect on discounting rates among heavy drinkers. Furthermore, it is unclear whether substance co-use and delay discounting are independently associated with AUD severity.

objectivesThe purpose of this study was to determine whether alcohol, tobacco, and cannabis co-use impacts delay discounting rates. We also sought to determine whether substance co-use and delay discounting were associated with AUD symptom counts.

methodsThe study sample was culled from several human laboratory studies and consisted of 483 heavy drinking individuals who completed a baseline visit (prior to experimental procedures). Participants were divided into groups based on self-reported alcohol, tobacco, and cannabis use during the past 30 days: alcohol only (n = 184), alcohol + cigarettes (n = 89), alcohol + cannabis (n = 82), and tri-use (n = 128). We examined discounting rates across the 4 groups and used multiple linear regression to test whether co-use and delay discounting were associated with AUD symptoms.

resultsAfter adjusting for covariates, individuals in the alcohol + cannabis group and the tri-use group had steeper discounting rates relative to the alcohol-only group. In addition, tri-use and delay discounting rates were independently correlated with a greater number of AUD symptoms.

conclusionsDelay discounting rates were significantly greater among subgroups reporting cannabis use providing partial support for an additive effect, while also highlighting the importance of co-use substance type. Both tri-use and delay discounting were associated with greater AUD severity, which may provide relevant intervention targets.

Indexed as

Alcoholic IntoxicationAlcoholismCannabisDelay DiscountingHallucinogensSubstance-Related DisordersTobacco ProductsAlcohol DrinkingEthanolHumansEthanolHallucinogensAlcoholAlcohol use disorderBehavioral economicsCannabisCo-useDecision-makingDelay discountingPolysubstance useTobacco

Identifiers

PMID34652499
PMCPMC9059652
OpenAlexW3205254903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.